(Q36424611)

14 August 2017

1 reference

title

The use of betaine in the treatment of elevated homocysteine (English)

1 reference

14 August 2017

Amy Lawson-Yuen

1

1 reference

PubMed ID

16545978

14 August 2017

Harvey L Levy

series ordinal

2

1 reference

14 August 2017

20 March 2006

1 reference

Molecular Genetics and Metabolism

14 August 2017

1 reference

14 August 2017

88

1 reference

14 August 2017

3

1 reference

14 August 2017

201-207

1 reference

Glycine betaine-assisted protein folding in a lysA mutant of Escherichia coli

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Chemical chaperones regulate molecular chaperones in vitro and in cells under combined salt and heat stresses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

A comparison of the GroE chaperonin requirements for sequentially and structurally homologous malate dehydrogenases: the importance of folding kinetics and solution environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Metabolic Abnormalities Detected in a Survey of Mentally Backward Individuals in Northern Ireland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

The identification of homocystine in the urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Dietary treatment of homocystinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Pyridoxine-dependency in homocystinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

The successful treatment of homocystinuria with pyridoxine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Treatment of homocystinuria with pyridoxine. A preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Treatment of homocystinuria with a low-methionine diet, supplemental cystine, and a methyl donor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

The use of betaine for the treatment of homocystinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Homocystinuria--the effects of betaine in the treatment of patients not responsive to pyridoxine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Homocystinuria due to cystathionine beta-synthase deficiency--the effects of betaine treatment in pyridoxine-responsive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Cystathionine beta-synthase deficiency: effects of betaine supplementation after methionine restriction in B6-nonresponsive homocystinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

HOMOCYSTINURIA: CLINICAL AND PATHOLOGICAL REVIEW OF TEN CASES.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

HOMOCYSTINURIA. STUDIES OF 20 FAMILIES WITH 38 AFFECTED MEMBERS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

The natural history of vascular disease in homocystinuria and the effects of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Strategies for the treatment of cystathionine beta-synthase deficiency: the experience of the Willink Biochemical Genetics Unit over the past 30 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Clinical heterogeneity and prognosis in combined methylmalonic aciduria and homocystinuria (cblC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Functional methionine synthase deficiency due to cblG disorder: a report of two patients and a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

The cblD defect causes either isolated or combined deficiency of methylcobalamin and adenosylcobalamin synthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Effect of betaine on S-adenosylmethionine levels in the cerebrospinal fluid in a patient with methylenetetrahydrofolate reductase deficiency and peripheral neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Methionine adenosyltransferase deficiency: new enzymatic defect associated with hypermethioninemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Cerebral edema associated with betaine treatment in classical homocystinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Serum total homocysteine and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Plasma homocysteine levels and mortality in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

A common 844INS68 insertion variant in the cystathionine beta-synthase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

A 31 bp VNTR in the cystathionine beta-synthase (CBS) gene is associated with reduced CBS activity and elevated post-load homocysteine levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Cystathionine beta-synthase polymorphisms and hyperhomocysteinaemia: an association study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Thermolabile methylenetetrahydrofolate reductase in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Treatment of mild hyperhomocysteinemia in vascular disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

The effect of low doses of betaine on plasma homocysteine in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Rett syndrome: model of neurodevelopmental disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.02.004

10.1016/J.YMGME.2006.02.004

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16545978